Valeant Pharmaceuticals International Inc. said late Tuesday that a Food and Drug Administration advisory committee voted unanimously to recommend approval for its psoriasis treatment brodalumab. Valeant said the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted 18 to 0 to approve brodalumab to treat moderate-to-severe plaque psoriasis. The FDA is not bound to its panels’ recommendation but generally follows their recommendations. Valeant has a license to market brodalumab in the U.S. from AstraZeneca PLC . Valeant shares declined 0.4% to $23.45 after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.